Search

Your search keyword '"Henry S. Friedman"' showing total 704 results

Search Constraints

Start Over You searched for: Author "Henry S. Friedman" Remove constraint Author: "Henry S. Friedman"
704 results on '"Henry S. Friedman"'

Search Results

1. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

2. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

3. Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis

4. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma

5. Adjunctive perampanel for glioma-associated epilepsy

6. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

11. Table S1 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

12. Supplementary Table 5 from Molecular Characterization of the Pediatric Preclinical Testing Panel

13. Figure S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

14. Data from Molecular Characterization of the Pediatric Preclinical Testing Panel

15. Supplementary Table 6 from Molecular Characterization of the Pediatric Preclinical Testing Panel

18. Supplementary Table 4 from Molecular Characterization of the Pediatric Preclinical Testing Panel

19. Figure S1- S10 from Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities

20. Data from Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma

21. Supplementary Table 3 from Molecular Characterization of the Pediatric Preclinical Testing Panel

22. Supplemental Dataset A - IDH1-R132H effect on the metabolome. from Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities

23. Data from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

24. Data from Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma

26. Supplementary Table S3 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

27. Supplementary Tables S1-S2 from Molecular Characterization of the Pediatric Preclinical Testing Panel

28. Data from Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities

30. Data from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

31. Supplemental Dataset B - GDH1/2 effect on the metabolome. from Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities

33. Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial

34. Abstract 4924: Alternative lengthening of telomeres is associated with hypersensitivity to topoisomerase 1 inhibition in glioblastoma xenograft models

35. Spiritual well-being and its association with health-related quality of life in primary brain tumor patients

36. CTIM-15. RESULTS OF A PHASE IB TRIAL OF RECOMBINANT POLIO:RHINOVIRUS IMMUNOTHERAPY FOR RECURRENT PEDIATRIC HIGH GRADE GLIOMA

37. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series

38. Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis

39. CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS)

40. QOL-08. PHASE II RANDOMIZED STUDY TO EVALUATE EFFICACY AND SATISFACTION OF ROLAPITANT PLUS ONDANSETRON VS. ONDANSETRON MONOTHERAPY IN PREVENTING NAUSEA/VOMITING FOR GLIOMAS RECEIVING RADIATION/TEMOZOLOMIDE

41. Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide

42. Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population

43. MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation

44. Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma

45. A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG)

46. A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma

47. Effects of Low-Dose Naltrexone on Quality of Life in High-Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial

48. QOLP-10. A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS

49. BIOM-20. TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM

50. IMMU-06. TARGETING IDH1 MUTANT GRADE II RECURRENT GLIOMAS USING A PEPTIDE VACCINATION STRATEGY

Catalog

Books, media, physical & digital resources